Clinical trials: Conjunctiva; Disorder
- Condition Conjunctiva; Disorder
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Allergic Conjunctivitis
A Six-Week Safety Study of an Investigational Ophthalmic Solution
The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.
- Trial name
- NCT01698814
- Testing
- AL-4943A Ophthalmic Solution, AL-4943A Ophthalmic Solution Vehicle
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Allergic Conjunctivitis
To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge
The purpose of the study is to determine whether Al38583 Ophthalmic Solution is safe and effective in reducing tear eosinophil levels at 5-8 hours after Conjunctival Allergen Challenge (CAC).
- Trial name
- NCT00881673
- Testing
- AL38583 Ophthalmic Solution, Maxidex, Vehicle
- Volunteers
- healthy volunteers welcome
- Sponsor
- Alcon Research
Eye Infections, Bacterial
Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers
To evaluate azithromycin ocular conjunctiva concentrations 7 and 14 days after treatment initiation. To assess ocular and systemic tolerance/safety and azithromycin tear concentrations on Day 7
- Trial name
- NCT00356772
- Testing
- Azithromycin
- Volunteers
- healthy volunteers welcome
- Sponsor
- Laboratoires Thea
Keratoconjunctivitis Sicca
TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
This is a prospective, observational case series to determine the clinical utility of tear osmolarity and other commonly used objective tests to diagnose dry eye disease, as well as to establish referent values for objective…
- Trial name
- CVS (NCT00848198)
- Where
- 10 sites in United States, France and 3 more
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- TearLab Corporation
Keratoconjunctivitis, Ocular Surface Disease
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
In this study, PP-001 eye drops are assessed for safety and tolerability in healthy, adult volunteers. PP-001 is a novel, anti-inflammatory small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase).
- Trial name
- NCT03769454
- Testing
- PP-001
- Where
- Austria
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Panoptes Pharma GmbH
Bacterial Conjunctivitis
Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
This is a seamless Phase I/II, randomized, double-masked, placebo-controlled, multicenter trial to evaluate single and multiple-dose safety and tolerability of SUM-191 in healthy participants in Parts 1 (SAD) and 2 (MAD) ; and…
- Trial name
- NCT07565103
- Testing
- SUM-191
- Where
- United States
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Senju USA, Inc.
Dry Eye Disease
Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S Lipid Balance, a new eye drops, emulsion developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT06323395
- Testing
- Vizol S LIPID BALANCE eye drops, ophthalmic saline eye drops
- Where
- 2 sites in Serbia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Eye Dryness
Comparison of Two Marketed Lenses in a Controlled Environment
This study is comparing two silicone hydrogel contact lenses in a controlled environment for identification of characteristics associated to vision.
- Trial name
- NCT02212301
- Testing
- senofilcon A, lotrafilcon B
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Allergic Conjunctivitis
A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults
The main goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles* of MDI-1228_mesylate Ophthalmic Solution in healthy adult participants.
- Trial name
- NCT05969236
- Testing
- MDI-1228_mesylate Ophthalmic Solution
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Medinno Pharmaceutical Technology Co., Ltd.
Allergic Conjunctivitis
Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)
To evaluate the efficacy of olopatadine 0.1% using the OHIO Chamber in patients with seasonal allergic conjunctivitis.
- Trial name
- NCT00818805
- Testing
- Olopatadine 0.1%, Tranilast 0.5%
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Keratoconjunctivitis Sicca
Tear Film Break-up Time After Instillation of Artificial Tears
This study is an exploratory trial evaluating the tear film break-up time after a single eye drop instillation of over-the-counter artificial tears.
- Trial name
- NCT00681265
- Testing
- glycerin, polyethylene glycol 400/propylene glycol
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Calm Water Therapeutics LLC
Allergic Conjunctivitis
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
This is a phase 2 study that will consist of 3 visits during a 3 week period conducted at up to 5 sites. The purpose of this study is to determine how effective the combination of Pred Mild® and FOV1101-00 is compared to either…
- Trial name
- NCT00833495
- Testing
- Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®)
- Where
- United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Fovea Pharmaceuticals SA
Allergic Conjunctivitis
Safety and Comfort of AL-4943A Ophthalmic Solution
The purpose of this study is to assess the ocular comfort and safety of olopatadine hydrochloride opthalmic solution. 0.7%.
- Trial name
- NCT01326858
- Testing
- Olopatadine hydrochloride ophthalmic solution, 0.7%, Olopatadine hydrochloride ophthalmic solution vehicle, Ketotifen fumarate ophthalmic solution, 0.025%
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Ophthalmological Agent Toxicity, Bacterial Conjunctivitis
Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects
This is a phase I clinical study evaluating the safety and tolerability of PRO-231 ophthalmic solution through the incidence of unexpected adverse events, incidence of conjunctival hyperemia and chemosis, changes in Best…
- Trial name
- NCT06363292
- Testing
- PRO-231, VIGAMOXI®
- Where
- Mexico
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Disease (DED)
Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye
The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S DIGI EYE, a new eye drops, solution developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to…
- Trial name
- NCT07050446
- Testing
- Vizol S DIGI EYE eye drops, 0,9% saline solution, eye drops
- Where
- 3 sites in Serbia
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Jadran Galenski laboratorij d.d.
Allergic Conjunctivitis
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
To evaluate the efficacy and safety of PR013 topical ophthalmic drops (0.045% and 0.06%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis using a modified Conjunctival Allergen Challenge…
- Trial name
- NCT03368339
- Testing
- PR013 (0.045%), PR013 (0.06%), Vehicle
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Realm Therapeutics, Inc.
Allergic Conjunctivitis
Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers
This study is being conducted to evaluate the safety of KetoNaph ophthalmic solution in healthy adult subjects and in pediatric subjects with a history or family history of ocular allergy.
- Trial name
- NCT01159015
- Testing
- KetoNaph, Vehicle
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers
The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers.
- Trial name
- NCT00889252
- Testing
- contact lens with ketotifen, contact lens
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Allergic Conjunctivitis
The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer
The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.
- Trial name
- NCT01346371
- Testing
- Refresh Tears 0.5% Lubricant Eye Drops, Bepreve 1.5% Ophthalmic Solution
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Minnesota Eye Consultants, P.A.
Allergic Conjunctivitis
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.
- Trial name
- NCT05815758
- Testing
- Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated